Professor John McMurray
- Professor of Cardiology (Cardiovascular & Metabolic Health)
telephone:
01413303479
email:
John.McMurray@glasgow.ac.uk
RC217Level C2, School of Cardiovascular and Metabolic Health, BHF Glasgow CRC, Glasgow G12 8TA
https://orcid.org/0000-0002-6317-3975Biography
John McMurray OBE, BSC (Hons), MB ChB (Hons), MD, FRCP, FESC, FACC, FAHA, FRSE, FMedSci
Professor McMurray is currently Professor of Medical Cardiology and honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.
Professor McMurray served as the inaugural Eugene Braunwald Scholar in Cardiovascular Disease at the Brigham and Women’s Hospital, Boston, and visiting Professor of Medicine, Harvard University, Boston, Massachusetts USA 2010/2011. He is a Past-President of the Heart Failure Association of the ESC.
He is a Highly Cited Researcher (https://recognition.webofscience.com/awards/highly-cited/2021/) and has a H-index of >200 (https://scholar.google.com/citations?user=n0ZdRMoAAAAJ&hl=en). He is and has been involved in many guideline committees, including chairing the Task Force for 2012 ESC Guidelines on heart failure and was a member of the 2016 and 2021 Task Forces. Professor McMurray is an Associate Editor for JACC-Heart Failure and is also a member of the editorial board of several journals including the European Journal of Heart Failure, Diabetes Care and the New England Journal of Medicine, and Guest Editor for Circulation & Circulation: Heart Failure. He is the Congress Programme Committee Chair for the European Society of Cardiology 2023/2024 and European Society of Cardiology Board Member.
Professor McMurray was a member of the recent European Society of Cardiology (ESC) Task Force that created a policy on gender https://www.escardio.org/static-file/Escardio/About%20the%20ESC/Documents/European%20Society%20of%20Cardiology%20Gender%20Policy.pdf and the NEJM policy group on diversity in research studies https://www.nejm.org/doi/full/10.1056/NEJMe2114651
He has won several awards, including the Stokes Medal of the Irish Cardiac Society. In June 2015, Professor John McMurray and Professor Salim Yusuf (McMaster University, Hamilton Ontario, Canada) were jointly awarded the 8th Arrigo Recordati International Prize for Scientific Research (for outstanding contributions in secondary prevention and risk reduction strategies in patients with cardiovascular diseases).
Professor McMurray is the recipient of the Mackenzie Medal, which is awarded by the British Cardiovascular Society in recognition of outstanding service to British Cardiology. He is also the recipient of the Louis and Artur Lucian Award for Research in Circulatory Diseases, which is awarded each year by McGill University, Montreal. This international award recognises outstanding research in the field of circulatory diseases by a scientific investigator, or group of investigators, whose contribution to knowledge in this field is deemed worthy of special recognition.
Professor McMurray was awarded an (honorary) OBE in 2019 by Her Majesty the Queen, in recognition of his services to cardiovascular research. In 2020 he was awarded the Gold Medal of the European Society of Cardiology, which the society describes as “the highest honour it can bestow on exceptional scientists for their contribution to cardiovascular medicine”. In 2021 Professor McMurray received the Rigshospitalet’s International KFJ Award. In 2023 he was made an honorary fellow of the Japanese Circulation Society. Professor McMurray has been invited to lecture widely at many international congresses and delivered many several named lectures.
Research interests
Research Theme: Cardiac Diseases
Prof McMurray’s primary research interests are in heart failure and the cardiovascular consequences of diabetes and chronic kidney disease, with a focus on clinical trials. He is, or was, the principal investigator, member of the executive committee or steering committee member for several large trials in his areas of interest including the completed CHARM-Added, CORONA, I-Preserve, EMPHASIS-HF, PARADIGM-HF, ATMOSPHERE, Harmony-Outcomes, PARAGON-HF, GALACTIC-HF, DAPA-HF, DAPA-CKD, ASCEND-D and -ND trials, DELIVER, the ongoing FINEARTS-HF trial and the recently announced FINALITY trial.
DAPA-HF trial website: www.dapatrial.org
DELIVER trial website: www.delivertrial.org
He has been a member and chair of many guideline committees and the lead author of the World Health Organization and first Scottish Intercollegiate Guidelines Network Guidelines on the Management of HF. In addition, he was a member of the 2008 ESC HF Guidelines Task Force, and Chair of the 2012 Task Force and member of the 2013 American College of Cardiology/American Heart Association HF Guidelines Committee and the 2014 National Institute for Health and Care Excellence (NICE) Acute HF Guideline Committee.
He is a member of NICE Appraisal Committee A and a member of the editorial board of the New England Journal of Medicine and sit on the editorial board of several leading cardiovascular journals, including the European Heart Journal (Associate Editor) and Circulation.
In 2013, Prof McMurray was identified as one of the 400 most influential biomedical researchers in the world and the only cardiovascular researcher on this list from the UK (Boyack KW, Klavans R, Sorensen AA, Ioannidis JP. A list of highly influential biomedical researchers,1996-2011. Eur J Clin Invest. 2013; 43:1339-65). I have also been included in the 2014, 2016, 2017 and 2018 Highly Cited Researchers listing and one of The World's Most Influential Scientific Minds: 2014 by Thomson Reuters.
Google Scholar
https://www.webofscience.com/wos/author/record/B-2467-2013
https://research.com/scientists-rankings/best-scientists/gb
Research groups
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Uncovering Patterns in Aggregated Datasets to Accelerate Personalizing Treatment of Heart Failure
American Heart Association (AHA)
2018 - 2019
- The effects of sacubitril/valsartan compared to valsartan on left ventricular remodelling in patients with asymptomatic left ventricular systolic dysfunction after myocardial infarction: a randomized, double blinded active-comparator cardiac-MR based trial
British Heart Foundation
2017 - 2020
- How do arrhythmias and conduction disturbances contribute to death or rehospitalisation in patients discharged following an admission with acute heart failure? A prospective, observational, multi-centre cohort-study
British Heart Foundation
2017 - 2022
- Aggregating Data to Accelerate Personalization of the Treatment of Heart Failure
American Heart Association
2017 - 2019
- British Society for Heart Failure (BSH) Research Fellow
British Society for Heart Failure
2016 - 2018
- Coronary Artery Disease in Heart Failure with Preserved Ejection Fraction
Chief Scientist Office
2016 - 2019
- Trends in infective endocarditis incidence, prevalence, and mortality in Scotland between 1986-2015
NHS Greater Glasgow and Clyde
2016 - 2017
- Longitudinal strain in patients admitted to hospital with heart failure: diagnostic utility and prognosis prediction (G47097 (14REF012CH03 CAMPBELL))
NHS Greater Glasgow and Clyde
2015 - 2016
- BHF centre of excellence
British Heart Foundation
2014 - 2019
- Palliative Care Needs in Patients with Heart Failure
British Heart Foundation
2013 - 2016
- Diuretics, Worsening Renal Function and Cardiorenal Outcomes in Heart Failure
European Society for Cardiology
2013 - 2013
- Clopidogrel compared to Aspirin in Chronic Heart failure (CACHE)"
Department of Health
2010 - 2015
- Effect of metformin on progression of carotid atherosclerosis in non-diabetic patients with CHD optimally treated with conventional risk reducing agents
Scottish Executive Health Department
2008 - 2012
- Microvolt T-wave alternans in chronic heart failure: a study of prevalence and incremental prognostic value.
Scottish Executive Health Department
2007 - 2009
- Microvolt T-wave alternans in chronic heart failure: a study of prevalence and incremental prognostic value.
NHS Endowment Funds
2007 - 2008
- Preventing hospitalisation early death from chronic heart failure in Primary Care:A randomised controlled trial of pharmacist-led medication review
Greater Glasgow Primary Care NHS Trust
2007 - 2009
- Stroke in Scotland 1986-2004:epidemiology and impact on population and health care
Scottish Executive Health Department
2007 - 2009
- Hydralazine in heart failure - a study of the mechanisms of action in human blood vessels
British Heart Foundation
2006 - 2009
- Long term consequences of socioeconomic deprivation on cardiovascular outcomes: a 25 year follow up of the Renfrew / Paisley
Scottish Executive Health Department
2005 - 2008
- High Fidelity Phenotyping combined with genomics, proteomics and metabonomics close to the patient
British Heart Foundation
2004 - 2008
- Can guiding medical treatment by measurement of blood N-terminal pro BNP concentration improve outcome in chronic heart failure?
British Heart Foundation
2004 - 2006
- Muscle wasting in chronic heart failure - a role for cyclin-dependent kinase inhibitors
British Heart Foundation
2003 - 2005
Supervision
- Beggs, Simon
. - Yeoh, Su Ern
Sodium and water homeostasis: The cornerstone of heart failure therapy.
